secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K/A
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001437749-24-003003
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra completes Acer acquisition; pro forma net loss $59.5M for 9-mo 2023
-------------------------------------------------------------------------

- Pro forma net loss of $59.5M for nine months ended Sep 30, 2023; $80.7M for FY 2022.
- Acer acquisition closed Nov 17, 2023; exchange ratio 0.1210 Zevra shares per Acer share plus CVR.
- Pro forma shares outstanding ~37.8M; Zevra issued ~2.96M shares for Acer equity.
- Zevra purchased Acer's SWK term loans ($18.2M) and Marathon convertible notes ($12.0M).
- Bridge loan of $10M provided to Acer; $1.5M anniversary payment due to Relief Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924003003/0001437749-24-003003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924003003/zvra20240126_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-003003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer